The FDA has noted both the lack of human clinical trial data and uncertainty about long-term safety
Cancer history, abnormal growths, edema, nerve symptoms, and glucose issues need clinician-guided interpretation
AOD9604 is a modified fragment of human growth hormone, primarily researched for its lipolytic (fat-reducing) properties without promoting cell proliferation or insulin resistance
boxed warning , the most serious type of warning from the Food and Drug Administration (FDA)
Long-Term Considerations: While individual responses vary greatly depending on personal health profiles discussed later below
Given that infants' gastrointestinal and metabolic systems are immature, even small exposures could theoretically affect glucose regulation, growth, or feeding patterns